Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic Prestige Cervical Disc “Not Inferior” To Fusion – FDA Panel

This article was originally published in The Gray Sheet

Executive Summary

Medtronic Sofamor Danek's Prestige ST artificial cervical disc should be approved, contingent upon postmarket submission of seven-year follow up data to help ensure long-term durability, FDA's Orthopedic & Rehabilitation Devices Panel recommended Sept. 19

You may also be interested in...



FDA Panel Favors Medtronic’s Bryan Cervical Disc Despite Durability Question

FDA's Orthopedic and Rehabilitation Devices Panel overwhelmingly supported approval of Medtronic Sofamor Danek's Bryan artificial cervical spinal disc, while acknowledging that the device's long-term durability is unknown

FDA Panel Favors Medtronic’s Bryan Cervical Disc Despite Durability Question

FDA's Orthopedic and Rehabilitation Devices Panel overwhelmingly supported approval of Medtronic Sofamor Danek's Bryan artificial cervical spinal disc, while acknowledging that the device's long-term durability is unknown

Medtronic Preps For Upcoming FDA Panel Meetings On Stent, Spinal Disc

Medtronic is preparing for FDA panel reviews of its Bryan cervical spinal disc in July and itsEndeavor stent this fall, the firm announced May 22

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024017

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel